A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective studySheri L. Spunt, Douglas S. Hawkins, Lynn Million et al.|The Lancet Oncology|2019Cited by 182
Evidence by Spectral Karyotyping that 8q11.2 Is Nonrandomly Involved in LipoblastomaZhong Chen, Amy Lowichik, Cheryl M. Coffin et al.|Journal of Molecular Diagnostics|2000Cited by 31
Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children’s Oncology Group study ARST0332.Sheri L. Spunt, Alberto S. Pappo, Lynn Million et al.|Journal of Clinical Oncology|2014Cited by 30
Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Childrens Oncology GroupLynn Million, R. Lor Randall, Andrea Hayes‐Jordan et al.|International Journal of Radiation Oncology*Biology*Physics|2021Cited by 15
Cytogenetic-clinicopathologic correlations in rhabdomyosarcomaZhong Chen, Holly Zhou, Susan Arndt et al.|Cancer Genetics and Cytogenetics|2001Cited by 11